OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Huey on Challenges Faced With Immunotherapy in HCC

June 20th 2020

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Dr. Wolf on the Design of GEOMETRY mono-1 Trial in METex14-Mutated NSCLC

June 20th 2020

Jüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.

Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCL

June 20th 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Talati on the Rationale for Venetoclax in AML

June 19th 2020

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Dr. Sokolova on the Rationale for Systematic Implementation of Germline Testing for Metastatic Prostate Cancer

June 19th 2020

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Dr. Dimopoulos on the Utility of Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

Dr. Morris on Deciding Among PET Tracers in Prostate Cancer

June 19th 2020

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

Dr. Kelly on Identifying Optimal Dose of Radium-223 and Niraparib in mCRPC

June 19th 2020

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Dr. Kuruvilla on the Treatment Landscape in Relapsed/Refractory Hodgkin Lymphoma

June 19th 2020

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

Dr. Sands on the FDA Approval of Lurbinectedin in Small Cell Lung Cancer

June 19th 2020

Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

Dr. Klein on Challenges With Active Surveillance in Prostate Cancer

June 19th 2020

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

Dr. Leonard on the FDA Approval of Tazemetostat in Follicular Lymphoma

June 18th 2020

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Dr. Jacobson on Design of ZUMA-5 Trial in R/R Indolent Non-Hodgkin Lymphoma

June 18th 2020

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Hoffman on the Mechanism of Action of PTG-300 in Polycythemia Vera

June 18th 2020

Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.

Dr. Rutherford on the Importance of Including Patients With Double-Hit Lymphoma in Clinical Trials

June 18th 2020

Sarah Rutherford, MD, discusses the importance of including patients with double-hit lymphoma in clinical trials.

Dr. Ghosh on the Need to Develop Novel Therapies in DLBCL

June 18th 2020

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

Dr. Katz on the Oncotype DX GPS Assay in Prostate Cancer

June 18th 2020

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Dr. Awad on Objectives of the Phase 2 GEOMETRY Mono-1 Study in NSCLC

June 18th 2020

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

Dr. Woyach on the Safety Profiles of BTK Inhibitors in CLL

June 18th 2020

Jennifer Woyach, MD, discusses the safety profiles of BTK inhibitors in patients with chronic lymphocytic leukemia.

Dr. Sartor on Outcomes With 177Lu-PSMA-617 After Radium-223 in mCRPC

June 18th 2020

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.